PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

– July 15, 2020) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (“PreveCeutical”), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program. This update of PreveCeutical’s Dual Gene Therapy Program, (see earlier release on January 14, 2020, and June 29, 2020), hasContinue reading “PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity”